GSK 1034702
Alternative Names: 1034702; GSK1034702; GSK1043702Latest Information Update: 10 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antidementias; Antipsychotics
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders in United Kingdom (PO, Liquid)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders in United Kingdom (PO, Tablet)
- 20 Apr 2011 Clinical development is ongoing in United Kingdom